SILO PHARMA, INC. Excess of Replacement or Current Costs over Stated LIFO Value
SILO PHARMA, INC. (SILO) had Excess of Replacement or Current Costs over Stated LIFO Value of $1.00 thousand as of 2021-12-31, per its 10-Q filed 2023-08-11.
Discontinued › Notes › Inventory
us-gaap:ExcessOfReplacementOrCurrentCostsOverStatedLIFOValue · last filed 2023-08-11
- 2021-12-31: Excess of Replacement or Current Costs over Stated LIFO Value $1.00K.
| Period end | Excess of Replacement or Current Costs over Stated LIFO Value |
|---|---|
| 2021-12-31 | $1.00K 10-Q · filed 2023-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |